Skip to main content
Almirall S.A. logo

Almirall S.A. — Investor Relations & Filings

Ticker · ALM ISIN · ES0157097017 LEI · 95980020140005007996 MC Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2020-12-15 Regulatory Filings
Country ES Spain
Listing MC ALM

About Almirall S.A.

http://www.almirall.com

Almirall S.A. is a global biopharmaceutical company specializing in medical dermatology. The company focuses on the research, development, manufacturing, and commercialization of proprietary medicines to address significant unmet needs in skin health. Leveraging scientific innovation, Almirall provides medical solutions designed to improve the well-being and quality of life for patients. Its operations encompass in-house research and development, strategic partnerships, and in-licensing to expand its portfolio of dermatological treatments.

Recent filings

Filing Released Lang Actions
La FDA aprueba Klisyri® (tirbanibulin) de Almirall, un nuevo tratamiento innovador tópico para la queratosis actínica
Regulatory Filings Classification · 95% confidence The document is dated December 15, 2020, and is titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) followed by a press release announcing the FDA approval of Klisyri® (tirbanibulin) by Almirall. It explicitly states, 'Almirall, S.A. (ALM.MC), en cumplimiento de lo dispuesto en la Ley del Mercado de Valores, anuncia que:' and concludes with 'Se adjunta el comunicado de prensa de Almirall.' This structure—an official announcement referencing compliance with market laws and attaching the full press release—is characteristic of a general regulatory disclosure or press release that is not one of the specific periodic reports (like 10-K or IR). Since it is a formal announcement of a significant event (drug approval) made to the market, and it is not a specific filing like a Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), it fits best under the general regulatory announcement category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, non-periodic, material corporate announcement that doesn't fit a more specific category like ER (Earnings Release) or CT (Call Transcript). The document length is substantial (15,269 chars), so it is the report itself, not just a notice of publication (RPA).
2020-12-15 Spanish
Operaciones del contrato de liquidez durante el tercer trimestre de 2020
Transaction in Own Shares Classification · 98% confidence The document is a formal announcement dated November 18, 2020, from Almirall, S.A., titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It explicitly details the operations (purchases and sales of shares) conducted under a pre-existing liquidity contract with Santander Investment Bolsa during the seventh quarter of its validity (July 1, 2020, to September 29, 2020). The text includes summary tables of these transactions and mentions that a detailed breakdown is attached. This type of filing, reporting on the company's own share transactions (repurchases/sales) under a specific program, directly corresponds to the definition of 'Transaction in Own Shares' (POS). It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a Director's Dealing (DIRS) as it concerns a corporate liquidity contract, not individual director trades.
2020-11-18 English
Consejo de Administración de la compañía
Board/Management Information Classification · 99% confidence The document is very short (646 characters) and announces a change in the composition of the Board of Directors: the designation of a new Second Vice President (Vicepresidente Segundo) and clarification of the role of the current Vice President. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2020-11-09 Spanish
Operaciones del contrato de liquidez durante el tercer trimestre de 2020
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement dated October 20, 2020, from Almirall, S.A., titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It explicitly states it is reporting on operations conducted under a liquidity contract ('contrato de liquidez') with Santander Investment Bolsa for the period from July 1, 2020, to September 29, 2020. The content details the number of shares bought and sold, and the cash involved, including a summary table and an attached detailed breakdown of daily transactions. This type of filing, reporting on insider/executive transactions or specific market operations like liquidity agreements, strongly aligns with the definition of Director's Dealing (DIRS) or, more broadly, a regulatory filing concerning share transactions. Since the document details transactions by an entity acting under a liquidity agreement (which often involves executives or related parties managing share price stability), and it is a specific regulatory disclosure to the CNMV (Spanish regulator), it fits best under the category for insider/executive transactions or a specific regulatory report. Given the options, 'Director's Dealing' (DIRS) is the closest fit for reporting on share transactions related to market management/insider activity, although it is specifically about a liquidity contract. However, if we consider the nature of the transaction (share buying/selling activity reported to the regulator), it is a specific transaction report. Since 'Transaction in Own Shares' (POS) is for the company buying back its own shares, and this is a liquidity contract, 'Director's Dealing' (DIRS) is often used as a proxy for significant share transaction disclosures by management/related parties, or it could fall under the general 'Regulatory Filings' (RNS). Looking closely at the content: it is a report of transactions executed under a liquidity agreement, which is a specific type of share transaction disclosure. If the transactions were explicitly by directors, DIRS would be perfect. Since it's a liquidity contract report, it is a specific regulatory disclosure. Given the detailed transaction data provided, it is more than just a general announcement (RPA/RNS). It is a report detailing share transactions. Since it is not explicitly the company buying back its own shares (POS), and it is a regulatory disclosure of transactions, 'DIRS' (Director's Dealing) is often the category used for reports detailing share transactions by insiders/related parties, or 'RNS' as a fallback. Given the context of reporting specific share movements to the regulator (CNMV), and the lack of a specific 'Liquidity Contract Report' code, 'DIRS' is a plausible classification for significant share transaction reporting, or 'RNS' as the general regulatory filing fallback. I will classify this as a specific regulatory filing detailing share transactions, which most closely resembles DIRS in scope of transaction reporting, but since it's a liquidity contract, RNS is safer if DIRS is strictly for directors' personal trades. However, liquidity contracts are often disclosed under insider/share transaction rules. I will lean towards RNS as the most accurate general regulatory filing category for this specific type of disclosure not explicitly covered elsewhere, as it is a 'Hecho Relevante' (Relevant Fact) filing. Revisiting definitions: DIRS is 'Report of personal share transactions by company directors and executives (insider trades)'. This is a report on a liquidity contract. POS is 'Report of the company buying back or selling its own shares'. This is executed by a third party under contract. Given the specific nature of reporting transactions to the CNMV, RNS (General regulatory announcements) is the most appropriate fallback when a specific code like 'Liquidity Report' is missing. I will use RNS.
2020-10-20 English
Admisión a cotización de acciones
Share Issue/Capital Change Classification · 95% confidence The document is very short (1040 characters) and announces that newly created shares (3,560,807) resulting from a capital increase related to a flexible dividend program have been admitted to trading on the stock exchanges as of October 12, 2020. This is a specific announcement regarding the capital structure and the listing of new shares. While it relates to capital, the core action is the admission to trading following a capital change. This fits best under 'Share Issue/Capital Change' (SHA) as it details the final step of a capital increase/share issuance process being listed, or potentially 'Capital/Financing Update' (CAP). Given the explicit mention of 'acciones nuevas' (new shares) being 'admitidas a cotización' (admitted to trading) following a capital increase, SHA is the most precise fit for reporting changes in the share count/structure.
2020-10-13 Spanish
Motivo de la notificación: Persona Estrechamente Vinculada
Director's Dealing Classification · 99% confidence The document is titled 'STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM'. This form explicitly details transactions (share movements, prices, volume) conducted by directors or persons closely associated with them. This directly corresponds to the definition of Director's Dealing (insider trades). The filing code for Director's Dealing is DIRS.
2020-10-09 Spanish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.